Education

1977     B. Pharm.                         (Banaras Hindu University, Varanasi )

1979     M. Pharm.                        (Banaras Hindu University, Varanasi)

1986     Ph. D.                                (Banaras Hindu University, Varanasi)

1987     Research Associate    (The University of Illinois, Chicago)

1989     Research Fellow           (Harvard University, Boston)

Honors & Awards

University Grants Commission Fellow, Government of India, 1977- 1979.

Prof. M.L. Schroff's Memorial Award for the best paper presentation at 34th Indian Pharmaceutical Congress

along with Golden Jubilee Celebrations of Pharmaceutical Education in India, Varanasi, December, 82.

Postdoctoral fellowship of NIDA research scheme in Department of Pharmacodynamics, College of Pharmacy,

University of Illinois at Chicago, U.S.A. 2nd Feb., 1987 to 31st August, 1989.

Research Fellowship in Department of Surgery, Harvard Medical School, Harvard University,

U.S.A. 1st Sept. 1989 to 31st August, 1990.

UGC Career Development Award, 1995. Not availed and joined NIPER

Dr. I. C. Chopra Award 2003, Regional Research Laboratory, Jammu

Dr. G. S. Sidhu Science Lecture 2005, Indian Institute of Chemical Technology

AICOI’s Punjab Ratan Award 2005, All India Conference of Intellectuals, Punjab

CDRI Oration Award 2005, Central Drug Research Institute, Lucknow

Mrs P.P.Suryakumari Prize (Gold Medal), 2005, Indian Pharmacological Society (IPS)

Rajbhasha Award 2008, Town official Language Implementation Committee (TOLIC), Chandigarh,

Home Ministry, Govt. of India

ISCB Award for Excellence 2009, Indian Society of Chemists & Biologists.

Pharma-Bio 2009 Award, CHEMTECH Foundation, Mumbai

Positions Held

Faculty Appointments

A.

Committees

1.

National

(i)

Chairman, Expert Committee to examine the applications for exemption from price control for drugs (DPCO, 95) constituted by the Ministry of Chemical & Fertilizers, Sept. 2004- till date

(ii)

Chairman, IDPL Revival Committee, Sept. 2004- Sept. 2005

(iii)

Chairman, Sub-group on Pharmacy Education of the working group on technical education for formulation of 11th five year plan under Ministry of HRD, Sept. 2006-

(iv)

Chairman, Board of Studies- Pharmacy, AICTE, March 2005- Aug. 2006

(v)

Chairman, Project Review and Steering Group (PSG) of Department of Information Technology, Oct. 2005- till date

(vi)

Chairman, Committee for setting up of new Institutes on the lines of NIPER, Dec. 2005- Jan. 2006

(vii)

Chairman, Sub Group III on R&D of The Working Group on Drugs & Pharmaceuticals, MCF. 11th Five Year Plan (2007-2012), June 2006- Sept 2006

(viii)

Member, PRDSF, DST, Feb. 2004 - Feb. 2007

(ix)

Member, DPRP, DST, Sept 2004- till date

(x)

Member, Investigational New Drug Committee, DCGI, GOI, Sept 2004- till date

(xi)

Advisory Member, USP-India, March, 2005

(xii)

Member, Working Group on Drugs & Pharmaceuticals, MCF. 11th Five Year Plan (2007-2012), May 2006- till date

(xiii)

Member, Steering Committee on “Development of Potential Drugs from the Ocean” (Drugs from the Sea), Feb. 2006- till date

(xiv)

Member, Expert committee of Drugs and Pharmaceutical Research Program, DST. 2007- till date

(xv)

Member, Indian Pharmacopoeia Commission, 2007 - till date

(xvi)

Member, Selection Committee for Faculty Positions of Panjab University (Nominee, Vice President of India), April 2009- March 2011

(xvii)

Member, Board of Studies in Human Genomics, Panjab University, Chandigarh, April 2009- March 2011

(xviii)

Member, Board of Studies in Biotechnology, Panjab University, Chandigarh,April 2009- March 2011

(xix)

Member, Advisory Committee, Nanotechnology/Biotechnology/Information Technology, Sri Guru Granth Sahib World University, Fatehgarh, Near Chandigarh, May 2009 - till date

(xx)

Organising Secretary, Indian Pharmacology Society -Annual Conference, November, 2007

(xxi)

Member, Executive Council of the Central University of Punjab, Bhatinda, August 2009 - 2012

(xxii)

Member, DOP, MCF Committee to review the report of Deloitte April 2009-June 2009

2.

Institute

I.

In -Charge -Administration, NIPER, December 1995.

II.

Chairman, Library Committee, NIPER, June 1996 - June2004

III.

Chairman, Screening & Selection Committee, NIPER 1996 -

IV.

Chairman, Computer Center Committee, NIPER, 1999 -

V.

Chairman, Committee for Setting up of new Institutes on the Lines of NIPER, Dec. 2005 - Jan. 2006

VI.

Member, Organizing Committee, Molecular basis of Drug Discovery and Development, NIPER, 1997.

VII.

Member, Organizing Committee, Indo-US symposium on Recombinant DNA Technology and its application in Drug discovery.

VIII.

Organizing Secretary, Emerging Trends in Cardiovascular Pharmac., Nov. 1999.

IX.

Member Secretary, Institutional Ethics Committee, NIPER, 1998 - 2004

X.

Member, Institutional Ethics Committee, NIPER, 2004 -

XI.

Chairman, Institutional Animal Ethics Committee, NIPER, 1998 -

XII.

Member, Editorial Team, CRIPS, a quarterly publication of NIPER, 2002-

XIII.

Member, Entrance Examination Committee, 2002-4

XIV.

Workshop Convener, Drug Discovery and Development in New Millennium, 2004

XV.

Member, DOP, MCF Committee to look into the placement mechanism of PG Students of NIPERs, May, 2009 - June, 2009

XVI.

Chairman, Joint Counseling Committee for admission to Masters Courses, NIPERs, 2007- till date

3.

University

(i)

Editor, Souvenir, 34th Indian Pharmaceutical Congress and Golden Jubilee of Pharmacy Education in India, December 1982, Varanasi.

(ii)

Member Local Organizing Committee, 34th Indian Pharmaceutical Congress, Varanasi, December 1982.

B.

Membership

Indian Pharmacological Society

Indian Pharmacy Graduates' Association

Indian Pharmaceutical Association

American Diabetic Association

Graduate Student Training/Experience

Thesis advisor of Ph. D.

(i)

Studies on opioid tolerance and dependence mechanisms (P. Tiwari, 1996).

(ii)

Iontophoretic transdermal delivery of model drugs (N. Kanikannan, 1997).

(iii)

Tolerance to kappa opioid-induced analgesia: Inhibition by ginseng saponins and their mechnism of action (N.V.S. Kumar, 2001).

(iv)

Role of Ca2+ channels in opioid induced pharmacological effects, tolerance and supersensitivity (S. Gullapalli, 2002).

(v)

Role of calcium channels and superoxides in angiotensin responses in diabetic rat thoracic aorta (K.H. Arun Kumar, 2004).

(vi)

Modulation of C-reactive protein (CRP) by reactive oxygen species in diabetes mellitus (E. Dhanraj, 2008).

(vii)

Role of PPARy on Angiotensin II mediated vascular responses of rats with insulin resistance (B. Viswanad, 2008).

(viii)

Characterization of 5HT2 receptors in thoracic aorta of insulin resistance rats (N. Silvia, ongoing).

(ix)

In vivo toxicity of nanoparticles (carbon nanotubes and polymeric nanoparticles) used in drug delivery (G. Chandraiah, ongoing)

(x)

In vitro effect of nanoparticles on macrophages (Raman Preet Singh, ongoing)

Thesis advisor of M. Pharm./M.Tech. /M.S. (Pharm.)/M.B.A. (Pharm.)

(i)

Effect of temperature on beta-adrenergic responses and study on newer beta-agonists and antagonists in rabbit jejunum (K. D. Datla, M. Pharm., 1985).

(ii)

Studies on calcium channel antagonists on rabbit jejunum (A. P. Sen, M. Pharm., 1985).

(iii)

Synthesis and biological activities of N-aryl N'- cyanoguanidines (K. Bangarurajan, 1984 Co supervisor).

(iv)

Studies on postsynaptic alpha adrenoceptors in thoracic aorta and vas deferens of rabbit and rat (P. Tiwari, M. Pharm., 1986).

(v)

Evaluation of toxicity and swimming activity of fish to phenol and cresol as water pollutants
(Manoj Kumar, M. Tech., 1990 co supervisor).

(vi)

Characterization of U-50, 488H, a kappa opioid agonist - withdrawal response in rabbit intestine
(M. Ramanathan, M. Pharm., 1994).

(vii)

Studies on calcium channel antagonists on Kappa opioid agonist - withdrawal responses in rabbit intestine
(N. M. Mahesh, M.Pharm., 1995).

(viii)

Characterization of ? - adrenoceptors in ventral lobe of rat prostate (M. Thiyagarajan, M.S., 1999).

(ix)

Characterization of alpha-adrenoceptors in vasdeferens of DOCA and vehicle treated rats
(S. Yogita, M.S., 1999).

(x)

Chronopharmacology of OP2 (k) opioid receptor mediated responses (T. Chacko, M.S., 1999).

(xi)

Studies on gastrointestinal responses to various agonists in control and streptozotocin induced diabetes animal models (M. Anjaneyulu, M.S.,1999).

(xii)

Studies on opioid receptor mediated effects in normal and streptozotocin induced diabetic rats
(K. Gurumoorthy, M.S., 2000).

(xiii)

Characterization of ?- adrenoceptors in vas deferens and aorta of streptozotocin induced diabetic rats
(N. Patel, M.S., 2000).

(xiv)

Characterization of ?- adrenoceptors in STZ induced diabetic rat prostate and vas deferens
(S. Jana, M.S., 2000).

(xv)

Studies on the high-fat diet rat model (insulin resistance) (P. Patole, M.S., 2000).

(xvi)

Tolerance to kappa and mu opioid induced analgesia: inhibition by melatonin and the role of BZD-GABAaergic mechanism (E. Dhanraj, M.S., 2001).

(xvii)

Selective attenuation of enhanced angiotensin II mediated responses in the streptozotocin diabetic rat thoracic aorta by tempol (B.N. Srikumar, M. S. , 2001).

(xviii)

In vitro studies on phenylephrine, 5-hydroxytryptamine and angiotensin II mediated responses in thoracic aorta of high fat diet fed rat (S. Ghatta, M. S. , 2001).

(xix)

Influence of ginseng total saponins (GTS) on opioid mediated immune effects in mice (V. Baburao M.S. , 2002).

(xx)

Effect of high fat diet and/or streptozotocin on angiotensin II mediated vascular responses in rat thoracic aorta: inhibition of enhanced responses by tempol (B. Viswanad, M.S.,2002).

(xxi)

Effect of donepezil and lercanidipine on memory impairment in intracerebroventricular STZ injected and high fat diet fed rats (S. Sonkusari, M.S., 2003).

(xxii)

Rosiglitazone attenuates the augmented vasocoatractile responses to angiotensin II and phenylephrine in thoracic aorta of high fat diet fed rats (C. Venkateswaran, M.S., 2003).

(xxiii)

Effect of in vivo and in vitro treatment with tempol on angiotensin II mediated vascular responses in thoracic aorta from high fat diet and or streptozotocin rats (L Asrat, M. S. Thesis, 2003).

(xxiv)

Licensing, An opportunity for Indian pharmaceutical firms in post WTO era (K. Alhad, MBA (Pharm.), 2003)

(xxv)

Advertising effectiveness of herbal hair and skin care products in India (F. Mehta, MBA(Pharm.), 2003).

(xxvi)

Effect of ß -Adrenergic Agents on Development of Opioid Induced Tolerance to Analgesia, Colonic Temperature and Cardiac Effects (M. Karwa, M. S., 2005).

(xxvii)

Effect of PPAR-y agonists on memory impairment induced by intracerebroventricular streptozotocin and high-fat diet fed rats (A.R. Pathan, M. S., 2005).

(xxviii)

Effect of PPAR-y agonists on augmented cardiovascular responses to angiotensin II in high fat diet (HFD)/and STZ treated rats (A. Gaikwad, M. S., 2005).

(xxix)

Development of a portal for ADME softwares with special reference to absorption (P. Gulati, M. S. Thesis 2005).

(xxx)

Development of a database for drug metabolism and toxicity with respect to cytochrome P450 enzyme & quantitative structure and LD50 value model for beta-adrenoreceptor blocking agents (J. S. Saini, M. S., 2005).

(xxxi)

Comparative study of angiotensin II type 1 receptor antagonism and PPAR-? activation on biochemical and vascular parameters of rats with insulin resistance (G. Chandraiah, M. S., 2006).

(xxxii)

Effect of nNOS inhibitor, 7-nitroindazole on the inhibitory effect of L-type calcium channel antagonist, nimodipine on the development of tolerance to morphine-induced analgesia (R. K. Singh, M. S., 2006).

(xxxiii)

To study the characteristics of L-type calcium channel associated with the supersensitivity to 5-HT mediated vascular responses and to determine the role of PPAR-? agonist in the thoracic aorta of rats with insulin resistance (A. Chourasia, M. S., 2006).

(xxxiv)

Evaluation of Atorvastatin and its combination with PPAR? agonists for biochemical parameters and vacular dysfunction in type 2 diabetic rat model (Sanjay Parmar M. S., 2007)

(xxxv)

Pharmacokinetic and Pharmacodynamic relationship of pentazocine in male Wistar rats
(Bhagwati Saxena, M. S., 2007)

(xxxvi)

Effect of NMDA antagonist memantine on the development of opioid tolerance
(Bharat Bhushan, M.S. Thesis 2008)

(xxxvii)

Role of endothelin in vascular complications in insulin resistant and diabetic rats ( Payal Gupta M.S., 2008)

(xxxviii)

Adverse effects of nanoformulations used in drug delivery (Umakant Ashok Bahira, M.S., 2008)

(xxxix)

Evaluation of hypoglycemic activity of marketed herbal anti-diabetic product momordica charantia
(Mukesh Meena, M. S. Thesis 2008)

(xl)

To study the effect of estrogen on vascular effect of a-adrenergic receptor in thoracic aorta of insulin resistant and type 2 diabetic male and female rats (Pawan Kumar, M. S., 2009)

(xli)

Autoprotection from acetaminophen hepatotoxicity by low dose of acetaminophen in type 2 diabetic rat (Ketan Mehta, M. S., 2009)

(xlii)

Evaluation of differences in the pharmacokinetic-pharmacodynamic relationship of morphine tolerant and naïve rat during different route of administration (Krishna Akkiseti. M. S., 2009)

(xliii)

Effect of cisplatin hepatotoxicty in type 2 diabetic mice (Anup Kumar Srivatsava, M. S., 2009)

(xliv)

Studies on PE, Ang II and 5-HT in abdominal aorta isolated from insulin resistance rats (Pinakin Karpe M. S., 2010)

(xlv)

In-silico prediction and in vivo/in vitro testing of mutagenicity (Murali Mishra, M. S., 2010)

(xlvi)

To study contractive responses of 5HT in isolated gastric fundus in diabetic rats (Deepak Deogade, M. S., 2010)

(xlvii)

Effect of Tempol on contractive reponses to PE, Ang II, ET-1 and 5HT on the thoracic aorta of diabetic rats (Ricky Marthong, M. S., 2010)

Teaching Experience

Pharmacology, (Toxicology including regulatory), physiology, biostatistics, computer applications in pharmacy to undergraduate and postgraduate students of pharmacy.

Training

Trainee, Warner-Hindustan Ltd., Hyderabad, May-June 1976.

Trainee, Duphar Interfran Ltd., Bombay, May-June 1977.

Supervisory Development Training, Ranbaxy Ltd., 1980.

Medline workshop, Library Health Sciences, University of Illinois, Chicago, 1987.

Participation In Scientific Meetings

Indian Pharmacological Society, Raipur, December, 1979

Indian Pharmaceutical Congress, Jaipur, December, 1981.

IPS Southern meet, Bangalore, May 1982.

IPS meeting, Chandigarh, November 1982.

IPC meeting, Varanasi, December 1982.

IPC meeting, New Delhi, December, 1985.

FASEB, Los Vegas, May 1988.

ASPET, Chicago Chapter Meeting, Chicago, May 1988

ASPET, Montreal, October 1988.

FASEB, New Orleans, March 1989.

ASPET, Utah, August 1989.

American Pancreatic Association Meeting, Chicago, November, 1989.

Indo - U.S. workshop on Current Approaches for receptor studies in neurobiology, Lucknow, September, 1991.

Indo - U.S. seminar on Recent Adv. in Pharmaceutical Sciences, Waltair, October 1991.

IPC meeting, Panjim, 1991

Intenational Seminar on Recent Trends in Pharmaceutical Sciences, Feb. 1995, Ooty.

IPS meeting, Patiala, November 1995

IPS meeting , Hyderabad, December 1996

International Symposium on Emerging Trends in Diabetes Mellitus and Hypertension, Ahemdabad, 4-6, Dec., 1997

Indian Physiological Society, Varanasi, Nov. 1998.

Indian Pharmacological Society Meeting, New Delhi, Dec., 1999.

Indian Pharmacological Society meeting , Ahmedabad, Dec., 2000

Indian Pharmaceutical Congress, New Delhi, Dec., 2001

GLP workshop, Chennai, Oct.2003

First Asian symposium for Pharmaceutical Sciences , Kyushu University, Japan 30-31 January 2004, Japan.

Indian pharmacological Society meeting, Kalkota, Jan 2005

Indo-Tunician Treaty Meeting, April 2005.

Indian pharmacological Society meeting, Jaipur, Dec 2006

American Heart Association’s ATVB Annual conference, Chicago, USA, 2007

Indian pharmacological Society meeting, S.A.S. Nagar, Nov., 2007

Indian Pharmaceutical Congress, Varanasi, Dec. 2007

Biotechnology Industry Organization (BIO 2008), San Diego, USA, June 2008

Indian pharmacological Society meeting, New Delhi, Dec2008

Biotechnology Industry Organization (BIO 2009), Atlanta, Georgia, USA, May 2009

Countries Visited

USA, Canada, Japan, Tunisia, Belgium, Netherland, Finland

Professional Service

Member, Advisory Board, Indian Journal of Pharmaceutical Sciences, 1996

Member, Editorial Board, CRIPS

Reviewer, Brain Research

Member, USP India Advisory Group

Research Grants/Projects

A.

Industry sponsored project

1) TITLE : "Mechanism of action of PRO-IMMU"

SOURCE: Envin Bioceuticals, Sharada Nagar, Saharanpur PROIMMU, a polyherbal formulation, containing immunomodulatory plant materials' action on mitogen induced lymphocyte proliferation and NK cell activity. The lymphocyte proliferation was estimated by thymidine incorporation using radiolablelled compound. Study of NK Cell activity with Pro-Immu treated mice against K 562 cell line. Chronic administration of PROIMMU in vivo is having an inverted U shaped dose response curve on mitogen induced proliferation. The effect of PRO IMMU on different hematological parameters is also investigated. Evaluation of antimutagenic activity of Pro-Immu against cyclophosphamide. The total funding of the project is Rs 1.40 lakhs

2) Title: Screening of Herbal Compounds

Source : Dabur India Ltd., New Delhi

Screening of polyherbal compounds and their formulations for anti-inflammatory, analgesic, immunomodulatory, anti-diabetic activity. The total funding of the project is Rs 6.00 lakhs

B.

CSIR sponsored work

Title: Opioid Tolerance and Dependence

i) To establish the cause and relationship in opioid tolerance and dependence and to inhibit and reverse the      development of tolerance and dependence to opioid agonists and establishment of their mechanism of action.

ii) NMITLI Project “ Oral delivery of insulin’ March, 2006 to Dec, 2008(Principal Investigator). The total funding of the      project is Rs 22.40 lakhs.

B. DST Sponsored

(i)

Transdermal Iontophoretic delivery of peptide /proteins : Aim of this proposal is to standardize the technique of transdermal iontophoresis for peptide/protein drugs working as co-principal investigator. The total funding of the project is Rs 13.64 lakhs.

(ii)

National Centre for Pharmacoinformatics (NCPI) for setting up of computational facility for pre clinical drug discovery: Principal Investigator (2005-2008). The total funding of the project is Rs. 1.5 Crores.

(iii)

Center for Pharmaceutical Nanotechnology (July 2006 -June 2011):Centre for pharmaceutical nanotechnology (CPN) establishment: (Principal investigator) objectives are “preparation, characterization pharmacodynamic & toxicity evaluation of drug loaded nanoparticles to treat cancer, hypertension, diabetes and metabolic syndrome” and Development of in vitro and in vivo models for the toxicological studies of nanoparticles used in drug delivery and biomedical applications. The total funding of the project is Rs. 9.59 Crores.

(iv)

Nano-toxicology project: “Facility Development for the toxicity screening of nanoparticles used for drug delivery and to elucidate its mechanism of action”: 2008-2011, 3 years (co- investigator). The total funding of the project is Rs. 2.24 Crores.

(v)

“Design and synthesis of dual PPAR ?/a agonist having noval carbazol moieties with antidiabetic and hypolipidemic activity” : (2005-2008) (co-investigator). The total funding of the project is Rs. 17.5 lacks.

C. NIPER sponsored

I) Genotoxicity testing

In vivo genotoxicity models, chromosomal aberrations and micronuclei testing in mouse were established and poly herbal formulations were screened for their inhibitory effects on cyclophosphamide induced genotoxicity in mice.

II) Title: Role of angiotensin II in hypertension.

Characterization of subtypes of angiotensin II (AT1 and AT2) receptors in hypertension and to determine the role of AT (1-7) in blood pressure regulation.

III) Title: Mechanisms underlying the insulin Resistance and screening of NCE for their anti-diabetic activity.

Development of animal models for the insulin resistance and investigating the mechanisms involved in insulin resistance and screening the NCEs for their anti-diabetic activity.

IV) Title: 28 day sub-chronic toxicity of NCE.

Carried out the sub-chronic toxicity studies of NCE as per the OECD guide lines.

OTHER ACTIVITIES

V) Instrumental in Initiation and Implementation of Institute’s policies in Central Animal Facility, NIPER. Well acquainted       with CPCSEA Rules and regulations.

VI) Instrumental in Initiation and Implementation of Institute’s policies in NIPER Library.

VII) Implementation of Information Technology applications in NIPER. Establishing the Internet connectivity and e- mail        facilities and coordinating them. Acquainted with WWW, HTML language and web page design.

VIII) Responsibility delegated as Head, management for the implementation of OECD GLP Principles . National Toxicology         Centre of NIPER is the first Government Institute declared as GLP certified laboratory.

IX)    Instrumental in initiating the Department of Pharmacy Practice as per Institutes’ policies

Patents :

1.

Venkat Ratnam D, Chandaraiah G, Sonaji K, Viswanad B, Bharadwaj V, Ramarao P, Ravi Kumar MNV. Design of biodegradable nanoparticles containing ellagic acid and coenzyme Q10 and their evaluation in Streptozotocin induced diabetic rats: A potential treatment strategy for diabetes and its complications. WTO Indian Patent No.1691/DEL/2006

2.

Ravi Kumar MNV, Kashyap N, Viswanad B, Bharadwaj V, Ramarao P, Neeraj Kumar. Design of glucose sensitive in-situ gelling system based on chitosan for pulsatile deliver of insulin, WTO Indian Patent No. 36/DEL/2006

3.

Ravi Kumar MNV, Ankola DD, Viswanad B, Bhardwaj V, Ramarao P. Biodegradable nanoparticles for oral delivery of coenzyme Q10. Indian Patent No. 18/DEL/2006

4.

Jain, R.; Jain, M.; Singh, P. P.; Singh, S.; Sachdeva, S.; Misra, V.; RamaRao, P.; Kaul, C. L. Ring-substituted 8-aminoquinoline analogues as antimalarial agents. 2003, Indian Patent No. 459/DEL/2003.

5.

Jain, R.; Jain, M.; Singh, P. P.; Singh, S.; Sachdeva, S.; Misra, V.; RamaRao, P.; Kaul, C. L. A process for preparation of ring-substituted 8-aminoquinoline analogues as antimalarial agents. Indian Patent No. 473/DEL/2003.

6.

Ramachandran U., Kumar, R. Mittal, A., Ramarao, P. Srinivasan, K. T., Dey, C.S., Ishrath, A, Chawla, H.P.S., Kaul,C.L., Tricyclic compounds having antioxidant properties. WTO Indian Patent No. 1268/DEL/2003.

7.

Jain, R.; Jain, M.; Singh, P. P.; Singh, S.; Sachdeva, S.; Misra, V.; RamaRao, P.; Kaul, C. L., Tikoo, K. A process for preparation of ring-substituted 8-aminoquinoline analogues as antimalrial agents. 2003. European Patent No. EP1606263.

8.

Jain, R.; Jain, M.; Singh, P. P.; Singh, S.; Sachdeva, S.; Misra, V.; RamaRao, P.; Kaul, C. L., Tikoo, K. A process for preparation of ring-substituted 8-aminoquinoline analogues as antimalrial agents. 2003. US Patent No. 6979740.

9.

Jachak S.M.; Ramachandran, U.; Mittal, A.; Srinivasan, K.; Ramarao, P.; Kaul, C.L. Naphthoquinone as antidiabetic agents. 2004. India WTO Patent No. 669/DEL/2004

Publications

Contributions to the referred Journals

The following is the data on 13.09.2009 from Scopus and Google Scholar

Total Citations          : 1178

Average citations  : 10.71

Range                         :  0 to 105

1.

V. P. Dadhania, D.N. Tripathi, A. Vikram, P. Ramarao, G. B.Jena, Chem Biol Interact. 183, 85-97 (2010).

2.

A. Vikram, G.B. Jena, P. Ramarao, Prostate, 70, 79-89 (2010).

3.

C. Gupta, A. Vikram, D.N. Tripathi, P.Ramarao, G.B. Jena, Phytother Res., 24, 119-28 (2010).

4.

K. Saandeep, A. Vikram, D.N.Tripathi, P. Ramarao, G.B.Jena, Basic Clin Pharmacol Toxicol., 105, 236-242 (2009).

5.

A. A. Pawar, A. Vikram, D.N. Tripathi, S. Padmanabhan, P. Ramarao, G.B. Jena, In Vivo., 23, 303-8 (2009).

6.

S. Padmanabhan, D.N. Tripathi, A. Vikram, P. Ramarao, Jena GB. Mutat Res. 673, 43-52(2009).

7.

E. Dhanaraj, A. Bhansali, S. Jaggi, P. Dutta, S. Jain, P. Tiwari, P. Ramarao. J Indian Med Assoc., 106, 366-372 (2009).

8.

J.N. Singh, G. Jain, P. Ramarao, S.S. Sharma, Indian J Physiol Pharmacol., 53,147-54 (2009).

9.

D.V. Ratnam, G. Chandraiah, A. K. Meena, P. Ramarao, M.N. Kumar, J Nanosci Nanotechnol. 9, 6741-6 (2009).

10.

G. Mittal, G. Chandraiah, P. Ramarao, M. N. Ravi Kumar, Pharm Res., 26, 218-23 (2008).

11.

S. Sundriyal, B. Viswanad, P. Ramarao, A. K. Chakraborti, P. V. Bharatam. Bioorg Med Chem Lett., 18, 4959-62 (2008). (1)

12.

A. Vikram, D. N. Tripathi, A. A. Pawar, P. Ramarao, G. B. Jena. Regul Toxicol Pharmacol., 52, 147-57 (2008).

13.

S. Padmanabhan, D. N. Tripathi, A. Vikram, P. Ramarao, G. B. Jena. Mutat Res., 655, 59-67 (2008). (1)

14.

A.R. Pathan, A.B. Gaikwad, B. Viswanad, P. Ramarao. Eur J Pharmacol., 589,176-9 (2008). (1)

15.

D.N. Tripathi, A.A. Pawar, A. Vikram, P. Ramarao, G.B. Jena. Mutat Res., 653,134-9(2008). (1)

16.

D. Venkat Ratnam, G. Chandraiah, K. Sonaje, B. Viswanad, V. Bhardwaj, P. Ramarao, M.N. Ravikumar, J Biomed Nanotech., 4, 1-11(2008). (2)

17.

S. Sundriyal, B. Viswanad, E. Bharathy, P. Ramarao, A.K. Chakraborti, P.V. Bharatam. Bioorg Med Chem Lett., 18,3192-5(2008). (1)

18.

A. Vikram, D.N. Tripathi, P. Ramarao, G.B. Jena. Toxicol Appl Pharmacol., 226, 84-93(2008). (4)

19.

E. Dhanraj, A. Bhansali, S. Jaggi, P. Dutta, S. Jain, P. Tiwari, P. Ramarao, Indian J. Med Res., 129, 506-514 (2008).

20.

A. Vikram, D.N. Tripathi, P. Ramarao, G.B. Jena. Regul Toxicol Pharmacol., 49, 238-44 (2007). (5)

21.

A.A. Pawar, D.N. Tripathi, P. Ramarao, G Jena. Phytother Res., 21,1221-7 (2007). (1)

22.

A. Vikram, P. Ramarao, G. Jena, Mutagenesis, 22,287-91(2007). (5)

23.

K. Srinivasan, P. Ramarao, Indian J Med Res., 125, 451-72. (14)

24.

D.D. Ankola, B. Viswanad, V. Bhardwaj, P. Ramarao, M.N. Kumar. Eur J Pharm Biopharm., 67,361-9. (8)

25.

A.B. Gaikwad, B. Viswanad, P. Ramarao, Pharmacol Res., 55, 400-7. (2)

26.

N. Kashyap, B. Viswanad, G. Sharma, V. Bhardwaj, P. Ramarao, M.N. Ravi Kumar, Biomaterials, 28, 2051-60. (11)

a. 2006

27.

A.R. Pathan, B. Viswanad, S.K. Sonkusare, P. Ramarao, Life Sciences, 79, 2209-16. (12)

28.

B. Viswanad, K. Srinivasan, C.L. Kaul and P. Ramarao, Pharmacological Research, 53, 209-215. (4)

a. 2005

29.

K.H.S. Arun and P. Ramarao, Pharmacological Research, 23, 1-16. (3)

30.

K.H.S. Arun, C. L. Kaul and P. Ramarao, Cardiovascular Research, 65, 374-86. (20)

31.

S. Sonkusare, C.L. Kaul, and P. Ramarao, Pharmacological Research, 51, 1-17. (91)

32.

K. Srinivasan, C.L. Kaul and P. Ramarao, Ind J Pharmacol., 37, 327-328. (5)

33.

G.B. Jena, C.L. Kaul, & P. Ramarao, Ind J Pharmacol, 37, 209-222.

34.

K.H.S. Arun, C. L. Kaul and P. Ramarao, Journal of Pharmacological and Toxicological Methods, 51, 1-23. (4)

35.

S. Ghatta, K. Srinivasan, C.L. Kaul and P. Ramarao: Pharmazie, 60, 142-6. (3)

36.

K. Srinivasan, B. Viswanad, L. Asrat, C. L. Kaul, and P. Ramarao: Pharmacological Research, 52,313-320. (47)

37.

S. Sonkusare, K. Srinivasan, C. L. Kaul, and P. Ramarao, Life Sciences, 77, 1-14. (15)

38.

R. Kumar, U. Ramachandran, K. Srinivasan, P. Ramarao, S. Raichur, and R. Chakrabarti: Bioorganic Medicinal Chemistry, 13, 4279-90. (11)

a. 2004

39.

K.H.S. Arun, C. L. Kaul and P. Ramarao: Journal of Hypertension, 22, 2143-52.

40.

K.H.S. Arun, C.L. Kaul and P. Ramarao, Pharmacological Research, 50, 561-8. (12)

41.

K. Srinivasan, P. Patole, C.L. Kaul and P. Ramarao, Methods & Finding in Experimental Clinical Pharmacology, 26, 327-33. (1)

42.

M. Jain, S. Vangapandu, S. Sachdeva, S. Singh P.P. Singh, G.B. Gena, K. Tikoo, P. Ramarao, C.L. Kaul, R. Jain: Journal of Medicinal Chemistry, 47, 285-287. (17)

43.

S. Mittal, A. Malde, C. Selvam, K.H.S. Arun, P.S. Johar, S. M. Jachak, P. Ramarao, P.V. Bharatam, and H.P.S. Chawla: Bioorganic Medicinal Chemical Letter, 14, 979-982. (4)

44.

U. Ramachandran, A. Mittal, P. V. Bharatam, S. Khanna, P. Ramarao, K. Srinivasan, R. Kumar, H. P. S. Chawla, C. L. Kaul, S. Raichur, and R. Chakraborti, Bioorganic Medicinal Chemistry, 12, 655-662. (1)

45.

Ghatta, S. and P. Ramarao, Lipids in Health and Disease, 3, 19.(3)

46.

E. Dhanraj, N. V. Kumar, P. Ramarao, Pharmacology Biochemistry & Behavior, 79, 733-7. (3)

a. 2003

47

M. Anjaneyulu and P. Ramarao, Methods & Finding in Experimental Clinical Pharmacology, 25, 205-8. (3)

48.

G.B. Jena, K.V.S. Nemmani, C.L. Kaul, P. Ramarao, Phytotherapy Research, 17, 306-10. (7)

49.

K.V.S. Nemmani and P. Ramarao, Life Sciences, 72, 759-68. (5)

50.

C. L. Kaul and P. Ramarao, In Atherosclerosis, Hypertension and Diabetes (ed). G. Pierce, M. Nagano, A. Zahradka, and N.S. Dhalla, Kluwer Academic Publishers, Boston, 139 - 154.

51.

54. B.N. Srikumar, C.L. Kaul and P. Ramarao In Atherosclerosis, Hypertension and Diabetes (ed). G. Pierce, M. Nagano, A. Zahradka, and N.S. Dhalla, Kluwer Academic Publishers, Boston, 327 - 338.

a. 2002

52.

G.B. Jena, C.L. Kaul and P. Ramarao, Indian Journal Pharmacology, 34, 86-99. (3)

53.

K.V. Nemmani and P. Ramarao, Pharmacol Biochem Behav 72, 1-6. (1)

54.

S. Gullapalli and P. Ramarao, Neuropharmacology, 42, 467-475. (13)

55.

K.V.S. Nemmani and P. Ramarao, Life Sciences, 70, 1727-1740. (6)

5 6.

S. Gullapalli, K.V.S. Nemmani, and P. Ramarao, Pharmacology Biochemistry & Behavior, 72, 93-99. (1)

57.

S. Gullapalli K. Gurumoorthy, C.L. Kaul and P. Ramarao, Europian Journal of Pharmacology, 435, 187-194. (6)

58.

K.V.S. Nemani, G. B. Jena, C.S. Dey, C.L. Kaul and P. Ramarao: Indian. Journal of Experimental Biology, 40, 282-287. (11)

59.

S. Gullapalli and P. Ramarao, Brain Research, 946, 191-197. (3)

60.

M. Thiyagarajan, C.L.Kaul and P. Ramarao, European Journal of Pharmacology, 453, 335-344. (7)

61.

S. Gullapalli and P. Ramarao, European Journal of Pharmacology, 451, 271-77. (6)

62.

M. Anjaneyulu and P. Ramarao, Methods Findings in Experimental & Clinical Pharmacology, 24, 71-75. (25)

63.

S. Shastri, V. Gopalakrishnan, P. Ramarao and H. Di Wang, J Hyperten., 20, 1381-1391. (34)

a. 2001

64.

C.L. Kaul and P. Ramarao, Progress in Drug Research, 57, 163 -180. (8)

65.

K.V.S. Nemmani, S. Gullapalli, P. Ramarao, Pharmacology, Biochemistry and Behavior, 69,189-193. (13)

66.

S. Shastri, J.R Mc Neill, T.W. Wilson, P. Ramarao, C.L. Kaul and V. Gopalakrishnan, American Journal of Physiology, 281, H342-H349.

67.

C.L. Kaul and P. Ramarao, Methods Findings in Experimental & Clinical Pharmacology, 23, 465-475. (10)

68.

N. Kanikkannan, J. Singh and P. Ramarao, Journal of Controlled Release, 71, 99 - 105. (26)

69.

P. Tiwari, P. Ramarao and S. Ghosal, Phytotherapy Research, 15, 177 -179. (7)

70.

R. Panchagnula, P. S. Salve, N. S. Thomas, A. K. Jain, and P. Ramarao, International Journal of Pharmaceutics, 219, 95-105. (45)

a. 2000

71.

N. Kanikkannan, J. Singh and P. Ramarao, International Journal of Pharmaceutics, 197, 69-76. (10)

72.

R. Panchagnula, O. Pillai, Nair, V.B. and P. Ramarao, Current Opinon in Chemical Biology, 4, 468 - 473. (27)

73.

K.V.S. Nemmani, S. Gullapalli, P. Ramarao, Pharmacy Pharmacology Communication, 6, 527 - 537. (4)

74.

C.L. Kaul and P. Ramarao, Drugs Today, 36, 699 - 713. (3)

a. 1999

75.

J. Jaiswal, P. Ramarao and R. Panchagnula: International Journal of Pharmaceutics, 179, 129-134. (1)

76.

V.B. Nair, O.P. Pillai, P. Ramarao and R. Panchagnula: Methods & Finding in Experimental and Clinical Pharmacology, 21, 139-151. (1)

77.

O.P. Pillai, V.B. Nair, P. Ramarao and R. Panchagnula: Methods & Finding in Experimental and Clinical Pharmacology, 21, 229 -240. (1)

78.

N. Kanikkannan, J. Singh and P. Ramarao, Journal of Controlled Release, 59, 99-105. (44)

79.

P. Ramarao and C. L. Kaul: Drugs Today, 35, 895 - 911. (14)

80.

P. Tiwar and P. Ramarao, Biogenic Amines, 15, 449 - 464.

a. 1996

81.

S. Ganga, P. Ramarao, J. Singh: Journal of Controlled Release, 42, 57-64. (32)

a. 1995

82.

N. Kannikanan, P. Ramarao and S. Ghosal: Phytotherapy Research, 9, 478 - 481. (7)

83.

P. Ramarao, K. T. Rao, R. S. Srivastava and S. Ghosal: Phytotherapy Research, 9, 66 -68. (7)

a. 1992

84.

P. Ramarao, A.K. Bhattacharya, A.P. Sen, Indian Journal of Experimental Biology, 30, 107-109.

85.

M. M. Lerch, A.K. Saluja, R. Dawra, P. Ramarao, M. Saluja. and M. L. Steer: Gastroenterology, 103, 205 - 213. (105)

86.

T. Hirano, A. Saluja, P. Ramarao, M. M. Lerch, M. L Steer: American Journal Physiology, 262, G439 -G444. (13)

a. 1991

87.

H.N. Bhargava, A. Gulati and P. Ramarao, Pharmacology, 42, 121 - 127. (14)

88.

P. Ramarao and H.N. Bhargava, General Pharmacology, 22, 521-525. (20)

89.

P. Ramarao, G. Matwyshyn and H.N. Bhargava, General Pharmacology, 22, 429-434. (12)

90.

H.N. Bhargava, A. Gulati and P. Ramarao, Biochemical Pharmacology, 42, 25-29. (2)

91.

T. Hirano, A. Saluja, P. Ramarao, M.M. Lerch, M. Saluja, and M.L. Steer, Journal of Clinical Investigation, 87, 865-869. (38)

a. 1990

92.

H.N. Bhargava and P. Ramarao, Neuropeptides, 15, 213-217. (7)

93.

A.P. Sen, S.K. Bhattacharya and P. Ramarao, Indian Journal of Experimental Biology, 28, 943-945.

94.

P. Ramarao and H.N. Bhargava: General Pharmacology, 21, 877- 880. (22)

a. 1989

95.

H.N. Bhargava, P. Ramarao, C. Richter and A. Beiniarz: Neuropharmacology, 28, 63-67. (6)

96.

. H. N. Bhargava, A. Gulati and P. Ramarao, Advances in Biosciences, 75, 695-698.

97.

P. Ramarao and H.N. Bhargava: Advances in Biosciences, 75, 723-726.

98.

H. N. Bhargava, P. Ramarao, A. Gulati,G.A. Matwyshyn and R. Prasad: Archives of International Pharmacodynamics & Therapeutics, 297, 247-259. (1)

99.

H. N. Bhargava, P. Ramarao and A. Gulati, G.A. Matwyshyn and R. Prasad, Pharmacology, 38, 243-252. (7)

100.

P. Ramarao and H.N. Bhargava: Pharmacology Biochemistry Behavior, 33, 375-380. (11)

101.

H.N. Bhargava, P. Ramarao, and A. Gulati: European Journal Pharmacology, 162, 257-264. (40)

102.

H.N. Bhargava, P. Ramarao and A. Gulati: Neuropharmacology, 28, 955-960. (7)

103.

H.N. Bhargava, A. Gulati and P. Ramarao, Journal of Pharmacology & Experimental Therapeutics, 251, 21-26. (84)

104.

H.N. Bhargava and P. Ramarao, Peptides, 10, 767-771. (11)

105.

A. Gulati, P. Ramarao and H.N. Bhargava, Pharmacology, 39, 145-153. (16)

106.

H.N. Bhargava and P. Ramarao, Life Sciences, 45, 2521-2528. (2)

107.

H.N. Bhargava, P. Ramarao, A. Gulati, K.P. Gudehithlu and G. A. Tejwani, Life Sciences, 45, 2529-2538. (15)

108.

H.N. Bhargava, P. Ramarao and A. Gulati, Progress in Clinical Biology Research, 328, 153-156.

109.

H.N. Bhargava and P. Ramarao, Progress in Clinical Biology Research, 328, 493-496.

110.

H.N. Bhargava and P. Ramarao, Progress in Clinical Biology Research, 328, 489-492.

a. 1988

111.

P. Ramarao and H.N. Bhargava, Pharmacology, 37, 1-7. (11)

112.

P.Ramarao, H.I. Jablonski, Jr., K.R. Rehder, and H. N. Bhargava: European Journal of Pharmacology, 156, 239-246. (55)

113.

H.N. Bhargava, P. Ramarao and A. Gulati, Pharmacology, 37, 356-364. (2)

a. 1980

114.

P. Ramarao, G. Jagadeesh and P. K. Das, Indian Journal of Experimental Biology, 19, 1154-1158.

Thesis

"Study of presynaptic alpha-adrenoceptors in rabbit jejunum". P. Ramarao, M. Pharm. Thesis, Banaras Hindu University, 1979.

Profile of postsynaptic alpha-adrenoceptors in rabbit intestine, thoracic aorta and vas deferens". P. Ramarao, Ph. D. Thesis, Banaras Hindu University, 1986.